Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by pierre013on May 11, 2017 10:34pm
365 Views
Post# 26235051

RE:RE:RE:AGM Perspectives

RE:RE:RE:AGM Perspectives
sah1 wrote: I am very happy to stand corrected:-. What PPPS capacity will be required to generate the $8B/yr  as this will be a critical factor as well in terms of timeframe?


Hi Sah1, like I said in a previous post, I asked the question to Pierre at the AGM and he came back with the explanation that Bruce Pritchard gave us with PLI's own capacity and the CMO's but that's about it.
I asked Fred the rough price of PG/L. and he answered around $ 1000 U.S./L. and with the graph presented on the capacity and revenue, it fits pretty well for PG deficiency but I think that it will be more valuable for Wound healing and other indications where micrograms are needed instead of milligrams. So I think the surprise will come from there. The revenue curve will expand vertically with the acute indications vs the needed quantity for PG deficiency.So nobody has the answer for now. For sure, from what Fred.told me,this part will be too large and PLI will need to partner PG for these indications. Exciting times ahead. 
Bullboard Posts